Arbutus Biopharma (ABUS) Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings or view top-rated stocks.

3 equities research analysts have issued 1-year price objectives for Arbutus Biopharma's shares. Their ABUS share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 200.0% from the stock's current price.
View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts.

Arbutus Biopharma's stock was trading at $2.33 at the beginning of 2023. Since then, ABUS shares have decreased by 14.2% and is now trading at $2.00.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our ABUS earnings forecast.

Arbutus Biopharma Co. (NASDAQ:ABUS) issued its quarterly earnings data on Thursday, August, 3rd. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.02. The biopharmaceutical company had revenue of $4.65 million for the quarter, compared to analyst estimates of $5.02 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 52.00% and a negative net margin of 309.89%.

ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Direxion mRNA ETF (MSGR) and iShares Genomics Immunology and Healthcare ETF (IDNA).ETFMG Treatments Testing and Advancements ETF (GERM).

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Arbutus Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.95%), Whitefort Capital Management LP (4.83%), Rubric Capital Management LP (2.03%), Hudson Bay Capital Management LP (1.70%), Geode Capital Management LLC (1.55%) and Woodline Partners LP (1.47%).
View institutional ownership trends.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABUS stock can currently be purchased for approximately $2.00.

Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $335.12 million and generates $39.02 million in revenue each year. The biopharmaceutical company earns $-69,460,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201.